Aranesp Sales Continue To Slide But Amgen Reports A Solid Year
During its fourth-quarter 2009 earnings call, Amgen also reported it has re-filed denosumab for osteoporosis with FDA.
During its fourth-quarter 2009 earnings call, Amgen also reported it has re-filed denosumab for osteoporosis with FDA.